Compare TransMedics Group Inc (TMDX) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Tripadvisor Inc Common Stock — how do they compare? TransMedics Group Inc trades at $79.01 (market cap $2.74B), while Tripadvisor Inc Common Stock trades at $8.94 (market cap $1.01B). The key difference: TransMedics Group Inc is far larger — about 2.7× Tripadvisor Inc Common Stock's market cap, and TransMedics Group Inc is more actively traded (949,331 versus 3,004,748). Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and Tripadvisor Inc Common Stock for 57 Days on average.
| TMDX | TRIP | |
|---|---|---|
Market Cap | $2.74B | $1.01B |
Volume | 949,331 | 3,004,748 |
Sector | Health | Consumer Cyclical |
52-Week High | $150.42 | $16.72 |
52-Week Low | $61.99 | $8.04 |
Typical Hold Time | 24 Days | 57 Days |
Enterprise Value | $3.13B | $1.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TMDX trades at $81.07, up 0.98% today, but faces a bearish technical signal with recent price weakness. Fundamentally, the company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying and ongoing legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 consensus target, supported by a 69% buy rating from analysts, but risks include earnings misses, margin pressure from heavy investment, and legal overhangs. Execution on growth amid rising costs remains critical for sustaining its premium valuation.
TripAdvisor (TRIP) trades at $8.63, up 1.29% on the day but near its 52-week low of $8.27. The stock is technically bearish, with recent earnings misses and a net cash outflow of $29M in 2025. Revenue grew to $1.89B in 2025, but net margins remain thin at 0.27%. Analyst sentiment is mixed, with a consensus price target of $13.58 but a majority hold rating.
The outlook is cautious. Upside potential exists if the Viator segment recovers and TheFork sale concludes, but risks include persistent earnings volatility, competitive pressure from AI travel tools, and weak cash flow trends. The stock offers value on P/S (0.57) but requires improved execution to justify higher multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
